Phase 3 Haemophilia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are a man who has been diagnosed with hemophilia B and are 18 years of age or older
- Your Factor IX (a clotting protein in the blood) activity level is 2% or lower, meaning your hemophilia is severe
- You do not have inhibitors (antibodies that block) Factor IX treatment
- You have received Factor IX treatment products on at least 150 separate days in the past
Who may not be able to join:
- You have a blood or bone marrow disorder other than hemophilia B
- You have previously received any type of gene therapy, including a treatment called ANB-002
- You have HIV that is not being successfully controlled with antiviral medication
- You currently have an active hepatitis B (HBV) or hepatitis C (HCV) infection
- You have certain antibodies in your blood called anti-AAV5 antibodies (confirm with trial site)
- You currently have any active widespread infection in your body, or you frequently get infections that require strong medication
- You have any other condition that causes your immune system to be severely weakened
- You have significant liver disease or any condition that may be a sign of an existing liver problem
- You have had cancer, unless you have been in full remission for more than 5 years
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Arina Arina V Zinkina-Orikhan, Biocad
Phone: +7 (812) 380 49 34
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Annualized bleeding rate (ABR) before and after a single dose of ANB-002
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.